Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure

Guimarães, Leonardo; Bergeron, Sébastien; Bernier, Martin; Rodríguez‐Gabella, Tania; Val, David del; Pîbarot, Philippe; Eigler, Neal; Abraham, William T.; Rodés‐Cabau, Josep

doi:10.4244/eij-d-19-00291

Cited by 27 publications

(31 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preliminary results of the latter trial on a total of 10 patients undergoing implantation of the second-generation V-Wave Shunt showed patency and absence of stenosis in all cases at the 1-year follow-up. Significant improvements in NYHA functional class (16.7% vs 100% of patients in class III-IV; P = 0.013) and 6-minute walking distance (338 ± 104 m vs 274 ± 65; P = 0.169) were also observed, suggesting continued efficacy of the device ( 105 ).…”

Section: Device-based Solutions For Hfpefmentioning

confidence: 98%

Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction

Rosalia

Ozturk

Shoar

et al. 2021

JACC: Basic to Translational Science

View full text Add to dashboard Cite

Highlights The prevalence of heart failure with preserved ejection fraction among patients who present with symptoms of heart failure is approximately 50%. Pharmacologic therapy has not conclusively shown benefits in morbidity and mortality in clinical trials. Although it represents an active area of research, no device-based therapy has received regulatory approval for the treatment of heart failure with preserved ejection fraction. Approaches such as atrial shunts, left ventricular expanders, mechanical circulatory support devices, and neurostimulators are at various stages of development.

show abstract

Section: Device-based Solutions For Hfpefmentioning

confidence: 98%

Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction

Rosalia

Ozturk

Shoar

et al. 2021

JACC: Basic to Translational Science

View full text Add to dashboard Cite

show abstract

“…The second-generation valveless V-wave shunt was studied in ten patients, which remained patent at one-year follow-up. 44 The efficacy of this device has been currently evaluated in a large randomized trial.…”

Section: Review Articlementioning

confidence: 99%

Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction

Bhardwaj¹,

Parikh²,

Nair³

2021

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome, which accounts for about 50% of patients with heart failure (HF). The morbidity and mortality associated with HFpEF is similar to HFrEF. Clinical trials to date have failed to show a benefit of medical therapy for HFpEF, which may due to lack of uniform phenotypes and heterogeneous population. In addition, medical therapy proven for HFrEF may not address the pathophysiologic basis for HFpEF. Left atrial remodeling and dysfunction is central to HFpEF and accounts for secondary pulmonary hypertension and pulmonary vascular congestion that frequently occurs with exertion. Interatrial shunts represent a novel treatment modality for HFpEF. These shunts allow for left atrial decongestion and a reduction in pulmonary venous hypertension during exercise leading to improvements in hemodynamics, functional status and quality of life. Trials to date have demonstrated safety and short-term efficacy of these devices for HFpEF. The long-term benefits are currently being evaluated in ongoing trials. If effective, the use of interatrial shunts may be a new therapeutic paradigm for the treatment of HFpEF.

show abstract

“…has been proposed recently. The left to right interatrial shunt enables decompression of the left atrium and thus may improve patient symptoms [6,7].…”

Section: A Novel Conception Of Therapy Based On Creating a Communicatmentioning

confidence: 99%

“…interatrial shunt device (IASD, Corvia Medical Inc., Tewksbury, MA, USA); V-Wave shunt (V-Wave Ltd, Caesarea, Israel) and the Atrial Flow Regulator (AFR, Occlutech, Heslingborg, Sweden). The initial safety and efficacy have been proved for the first two devices in small studies [6,7]. Atrial Flow Regulator is a self-expandable double-disc nitinol wire mesh construction allowing communication across the interatrial septum.…”

Section: A Novel Conception Of Therapy Based On Creating a Communicatmentioning

confidence: 99%

Pomeranian atRial flOw reguLatOr iN conGestive hEart failuRe (PROLONGER): Study protocol

Lewicki¹,

Kosmalska

Liedtke³

et al. 2020

Cardiol J.

View full text Add to dashboard Cite

Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure

Cited by 27 publications

References 4 publications

Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction

Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction

Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction

Pomeranian atRial flOw reguLatOr iN conGestive hEart failuRe (PROLONGER): Study protocol

Contact Info

Product

Resources

About